Authors
Latest:
Dr Das on the Landscape of Current and Emerging ADCs in SCLCMillie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.
Latest:
Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial CarcinomaSebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.
Latest:
Dr Biachi on the Growing Treatment Landscape in HCCTiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.
Latest:
Women in Oncology: Leukemia Therapies in Humans, for HumansJudith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Latest:
Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening RatesIsabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.
Latest:
Dr Anders on the Investigation of CCR4 Antagonists in Advanced CancersRobert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.
Latest:
Future Management of Chronic Myeloid LeukemiaClosing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
Latest:
Dr Jimenez on the Radiation Treatment Paradigm in Breast CancerRachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.
Latest:
Dr. Kazmi on Key Treatment Considerations for Young-Onset CRCSyed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.
Latest:
Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALLWith their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Latest:
Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical CancerYovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.
Latest:
Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate CancerAndrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Balzarotti on the Challenges of Treating Elderly DLBCLMonica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.
Latest:
Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast CancerDenise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.
Latest:
Dr. Kundranda on the Sequencing of Second-Line Therapies in HCCMadappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.
Latest:
Dr. Michalski on the Goals ASTRO in Radiation OncologyJeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.
Latest:
Immunotherapy Paves Path for New Standards of Care in Gastroesophageal CancersIt is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.
Latest:
Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold TumorsJonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.
Latest:
Best Practices for Virtual Conference PresentationsAs the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.
Latest:
Using Systemic Therapy to Treat HER2+ Breast CancerClosing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
Latest:
Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCCVishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.
Latest:
Expanding Cancer Screening: The Future of Blood-Based TestingClosing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Latest:
Dr Appel on the Significance of International Childhood Cancer DayBurton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.
Latest:
Clinical Pearls and Closing Thoughts on NSCLC Treatment LandscapeClosing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Latest:
Palliative Care for Young Adults Is a Growing Reality in CRCAlthough most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.
Latest:
Future Outlooks in the Treatment of R/R DLBCLShared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Latest:
Case Studies with Hepatic Artery InfusionRyan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, review cases of patients with colorectal cancer and provide insights on clinical practice.
Latest:
Dr Lee on Head and Neck Cancer Updates from the 2024 ACRO SummitAnna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.
Latest:
Addressing Treatment Gaps in HER2+ MBCUnmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
